Compare PROV & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROV | BMEA |
|---|---|---|
| Founded | 1956 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.1M | 96.9M |
| IPO Year | 1996 | 2021 |
| Metric | PROV | BMEA |
|---|---|---|
| Price | $15.38 | $1.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $16.25 | $8.71 |
| AVG Volume (30 Days) | 5.9K | ★ 1.2M |
| Earning Date | 10-28-2025 | 11-04-2025 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $39,823,000.00 | N/A |
| Revenue This Year | $4.14 | N/A |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | $17.06 | ★ N/A |
| Revenue Growth | ★ 0.07 | N/A |
| 52 Week Low | $12.98 | $0.87 |
| 52 Week High | $16.70 | $7.06 |
| Indicator | PROV | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 47.02 | 48.12 |
| Support Level | $15.01 | $0.95 |
| Resistance Level | $15.65 | $1.12 |
| Average True Range (ATR) | 0.41 | 0.11 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 34.07 | 53.24 |
Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. It is a financial services company committed to serving consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its business activities consist of community banking, investment services and trustee services for real estate transactions. The group operates in Bank segment that include attracting deposits, offering banking services and originating and purchasing single-family, multi-family, commercial real estate, construction and, to a lesser extent, other mortgage, commercial business and consumer loans. Its evenues are derived from interest earned on its loan and investment portfolios, and fees generated through its community banking activities.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.